XML 14 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Operating activities:    
Net loss (unaudited) $ (47,712) $ (1,909)
Adjustments to reconcile net loss to net cash from operating activities:    
Research and development expense, Patent cost 42,259
Depreciation expenses 6 5
Changes in operating assets and liabilities:    
Advances to suppliers (117) (21)
Prepaid expenses 45
Other current assets 130 (11)
Other noncurrent assets (82) (27)
Accounts payable 568 115
Amounts due to related parties (203) (24)
Accrued expenses (97) (120)
Other current liabilities (76) 1
Net cash used in operating activities (5,279) (1,991)
Investing activities:    
Acquisitions of property and equipment (14)
Net cash used in investing activities (14)
Financing activities:    
Proceeds from issuance of ordinary shares, net of underwriting discount 50,505
Payment of initial public offering costs (2,334) (42)
Net cash provided by (used in) financing activities 48,171 (42)
Effect of foreign exchange rate changes, net (1) 7
Net (decrease) increase in cash and cash equivalents 42,877 (2,026)
Cash at beginning of period 11,687 10,821
Cash at end of period 54,564 8,795
Non-cash activities:    
Initial public offering costs accrued in accrued expenses and other current liabilities 55
Research and Development Expenses Settled by Shares Issuance $ 42,259